Skip to content

In the BioHarmony Drug Report Database

Avapritinib

Ayvakit, Ayvakyt (avapritinib) is a small molecule pharmaceutical. Avapritinib was first approved as Ayvakit on 2020-01-09. It is used to treat gastrointestinal stromal tumors in the USA. It has been approved in Europe to treat gastrointestinal stromal tumors. The pharmaceutical is active against mast/stem cell growth factor receptor Kit and platelet-derived growth factor receptor alpha. Ayvakit's patent is valid until 2034-10-15 (FDA).
Trade Name Ayvakyt
Common Name Avapritinib
Indication gastrointestinal stromal tumors
Drug Class Tyrosine kinase inhibitors
Avapritinib
Get full access now